Wednesday, July 22, 2026 Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033)Prognosis in low-grade gliomas (LGGs) remains highly variable, and treatment-related late toxicity is a concern. This trial was comparing single-modality therapies in patients who often survive for years or decades and investigating differential responses according to molecular markers. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E, Philips C, Kros JM, Bady P, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Jacob J, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Balana C, Azevedo ALS, Clement PM, Berghoff A, Tzuk-Shina T, Weller M, Nordal RA, Rees J, Lacombe DA, Mason WP, Stupp R. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU) (ONLINE). Journal of Clinical Oncology 2026. https://ascopubs.org/doi/abs/10.1200/JCO-25-02735
